Close
Enter your
text here

TEVG

Tissue Engineered Vascular Grafts: A Breakthrough for Children With Heart Defects
 Tissue Engineered Vascular Grafts: A Breakthrough for Children With Heart Defects 968 1024 Abbie Miller
By: Abbie Miller
Illustration of a heart showing the Fontan surgery

An innovation 30 years in the making is poised to change the way children with single ventricle disease experience life after a Fontan procedure. Children with single ventricle disease are often described as having “half a heart.” What this really means is that one of their ventricles (either the right or left lower chamber of…

Don’t Oversize Your Tissue-Engineered Vascular Grafts: Insights for the Translation of New Surgical Technologies
 Don’t Oversize Your Tissue-Engineered Vascular Grafts: Insights for the Translation of New Surgical Technologies 1024 683 Abbie Miller
By: Abbie Miller

Study shows that adoption of a tissue engineered vascular graft technology currently in clinical trials would require a shift in surgical approach. Tissue engineered vascular grafts (TEVGs) are designed to overcome two important problems associated with synthetic conduits used in surgeries for children with congenital heart disease (CHD): the lack of growth potential and the…

Researchers Characterize Growth and Remodeling of Tissue-Engineered Blood Vessels
 Researchers Characterize Growth and Remodeling of Tissue-Engineered Blood Vessels 600 400 Lauren Dembeck
By: Lauren Dembeck
Tissue engineered vascular graft

Tissue engineering may soon give babies with congenital heart disease new blood vessels capable of native function and growth.   Major cardiovascular reconstructive operations in babies with congenital heart defects require the use of artificial blood vessels called vascular grafts. Because these grafts are made of man-made materials, the recipients’ tissues eventually begin to outgrow…

Growing Opportunities for Tissue Engineering
 Growing Opportunities for Tissue Engineering 150 150 Katie Brind'Amour, PhD, MS, CHES
By: Katie Brind'Amour, PhD, MS, CHES

A new system removes much of the expense and technical challenges surrounding cell seeding of tissue-engineered vascular grafts, making the technology more accessible to patients everywhere. One of the key challenges in congenital heart surgery is that current grafts used to correct heart defects are not living grafts—they don’t grow with the patient or function…